Buffett Grabs More of This Stock, Plus Other Notable Insider Buying frender / iStock via Getty Images At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant’s tracking stocks, even with shares still in retreat. Meanwhile, a couple of industrials and a couple of biotechs also saw notable insider purchases made in the past week. Overall, insider buying has slowed. A well-known adage ...

公司介绍 - Acrivon Therapeutics是一家在纳斯达克上市的临床阶段生物制药公司，专注于开发精准肿瘤治疗药物，通过其专有的蛋白质组学患者反应者识别平台AP3，将药物与预测对特定药物敏感的患者匹配[1] 企业活动 - 公司将于2024年4月24日举行虚拟企业研发活动，将由Acrivon的领导团队进行演讲，并进行互动问答环节[2] 领导团队演讲内容 - Acrivon的首席执行官Peter Blume-Jensen表示，公司将分享AP3驱动的产品线的关键更新，以及展示其精准磷酸蛋白组学方法的强大之处，同时还将提供ACR-368临床数据和其他管道进展的预演示[3]

融资公告 - Acrivon Therapeutics (NASDAQ:ACRV) 宣布进行了一项价值1.3亿美元的私募融资[1] - 公司以每股8.5美元的价格出售了8,235,000股ACRV股票[2] - 该融资还包括以每股8.49美元出售的7,060,000股预先融资认股权证，行权价格为1美分[3]

WATERTOWN, Mass, April 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced that it has entered into a securities purchase a ...

小盘股投资机会 - 小盘股目前有很好的投资机会，原因包括：预期的美联储宽松政策可能会提振小盘股，小盘股在过去五年中表现不佳，有望回归均值，科技行业的涨势可能会放缓或逆转，这对大盘指数如标普500指数有不成比例的好处[1] - 投资者可以考虑投资IWM、IJR、VB、AVUV等跟踪小盘股指数的ETF和基金[13][14][15] 罗素2000指数分析 - 最近在Seeking Alpha上写了一篇文章建议投资者卖出罗素2000指数和跟踪该指数的ETF，如IWM、VRTIX和VTWO，因为它们的负阿尔法（较低的回报和较高的风险）受到影响。这主要是由于罗素2000每年六月第四个星期五重新平衡股票时的季节性因素，以及此时发生的交易成本升高。在2016年至2023年的八年中，罗素2000在5、6、7和8月份的总体表现比标普500指数低了28.4%[2] - 根据2024年2月29日的数据，罗素2000指数中约30%的公司盈利为负。在过去，这些公司的负收益与盈利公司的收益相抵消，导致超过100的市盈率。现在，罗素将无盈利公司的数据排除在外，以计算其市盈率。在我看来，它在2004年2月29日报告的排除负收益后的市盈率为16.47是没有意义的[8] 指数比较分析 - 根据2024年3月28日的数据，标普500指数、标普小盘600指数、CRSP美国小盘指数和罗素2000指数的市值、重新平衡频率、股票数量、最大和最小市值、中位数、平均值、收益率、标准差、市净率和市盈率等方面存在差异[4] - 标准差方面，标普500指数、标普小盘600指数、CRSP美国小盘指数和罗素2000指数的数据分别为17.63%、20.82%、20.34%和21.29%[5] - P/B比率方面，标普500指数、标普小盘600指数、CRSP美国小盘指数和罗素2000指数的数据分别为4.50、1.64、2.33和1.77[5] - P/E比率方面，标普500指数、标普小盘600指数、CRSP美国小盘指数和罗素2000指数的数据分别为21.76、15.39、17.53和无意义[5] 小盘指数表现分析 - 比较三个小盘指数时，每个指数的标准差相似。在过去的十年中，表现最好的指数大多是标普600指数，而在过去12个月和年初至今，CRSP的回报明显高于其他两个指数，尽管仍略低于标普500指数。除了重新平衡频率之外，这三个指数之间还有几个其他影响表现的重要差异[10]

Exhibit 99.1 Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, March 28, 2024 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________________ TO ____________________ Commission File Number 001-41551 Acrivon Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Del ...

ACR-2316, a novel, selective dual WEE1 and PKMYT1 inhibitor development candidate, designed using AP3 to achieve superior single agent activity, demonstrates potent preclinical activity across studies AP3 identified mechanism of resistance to ACR-368, a clinical-stage CHK1/2 inhibitor, as well as a rational combination treatment to overcome resistance through sensitization to ACR-368 via ultra-low dose gemcitabine WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or ...

ACR-2316, a novel, selective dual WEE1 and PKMYT1 inhibitor development candidate, designed using AP3 to achieve superior single agent activity, demonstrates potent preclinical activity across studies AP3 identified mechanism of resistance to ACR-368, a clinical-stage CHK1/2 inhibitor, as well as a rational combination treatment to overcome resistance through sensitization to ACR-368 via ultra-low dose gemcitabine WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or ...

WATERTOWN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Ivana Magovčević-Liebisch, P ...